DELFI Diagnostics is a precision oncology company, founded in 2019 and built on research from the Johns Hopkins Kimmel Cancer Center, that combines machine learning with genome-wide analysis of cell-free DNA fragmentation patterns (an approach it calls DNA fragmentomics, or "fragmentomes") to develop accessible, blood-based cancer screening and… - View it on GitHub